Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin (Q82941854)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

title

Tissue-specific signatures of activating PIK3CA and RAS mutations in carcinosarcomas of gynecologic origin (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

author name string

Whitfield B Growdon

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Breton N Roussel

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Vanessa L Scialabba

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Rosemary Foster

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Dora Dias-Santagata

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

A John Iafrate

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Leif W Ellisen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Rosemary H Tambouret

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Bo R Rueda

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

Darrell R Borger

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

publication date

17 December 2010

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

volume

121

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

page(s)

212-217

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

Chemotherapy for malignant mixed Müllerian tumors of the ovary

18 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Analysis of clinicopathologic factors in malignant mixed Müllerian tumors of the uterine corpus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Cisplatin as initial chemotherapy in ovarian carcinosarcomas: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

The role of radiation in improving survival for early-stage carcinosarcoma and leiomyosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Phase III Trial of Ifosfamide With or Without Paclitaxel in Advanced Uterine Carcinosarcoma: A Gynecologic Oncology Group Study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

The impact of multi-modal therapy on survival for uterine carcinosarcomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Molecular genetic evidence for the conversion hypothesis of the origin of malignant mixed müllerian tumours

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

DNA mismatch repair and TP53 defects are early events in uterine carcinosarcoma tumorigenesis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Carcinosarcomas (Malignant Mullerian Mixed Tumors) of the Uterus and Ovary: A Genetic Study With Special Reference to Histogenesis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Carcinosarcomas (malignant mixed mullerian tumors) of the female genital tract: comparative molecular analysis of epithelial and mesenchymal components

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Uterine carcinosarcomas (malignant mixed Mullerian tumors) are metaplastic carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Malignant biphasic uterine tumours: carcinosarcomas or metaplastic carcinomas?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

A clinical and biological comparison between malignant mixed müllerian tumors and grade 3 endometrioid endometrial carcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Malignant mixed müllerian tumor versus high-grade endometrial carcinoma and aggressive variants of endometrial carcinoma: a comparative analysis of survival

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Endometrial carcinosarcomas have a different prognosis and pattern of spread compared to high-risk epithelial endometrial cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Ovarian and uterine carcinosarcomas: a comparative analysis of prognostic variables and survival outcomes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Molecular genetic aberrations of ovarian and uterine carcinosarcomas--a CGH and FISH study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

ERBB-2 gene overexpression and amplification in uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Different expression patterns of KIT, EGFR, and HER‐2 (c‐erbB‐2) oncoproteins between epithelial and mesenchymal components in uterine carcinosarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

EGFR expression and HER2/neu overexpression/amplification in endometrial carcinosarcoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Low frequency of somatic mutations in uterine sarcomas: a molecular analysis and review of the literature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Expression and amplification of HER-2/neu oncogene in uterine carcinosarcomas: a marker for potential molecularly targeted treatment?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

COX-2, c-KIT and HER-2/neu expression in uterine carcinosarcomas: prognostic factors or potential markers for targeted therapies?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Uterine carcinosarcoma: immunohistochemical studies on tissue microarrays with focus on potential therapeutic targets

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Carcinosarcoma of the uterus: immunohistochemical and genetic analysis of clonality of one case

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

7 January 2021

Endometrial Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

High frequency of coexistent mutations of PIK3CA and PTEN genes in endometrial carcinoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

A gynecologic oncology group randomized phase III trial of whole abdominal irradiation (WAI) vs. cisplatin-ifosfamide and mesna (CIM) as post-surgical therapy in stage I-IV carcinosarcoma (CS) of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Management of malignant, mixed mesodermal tumors of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Adjuvant chemotherapy in early uterine sarcoma

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Adjuvant ifosfamide and cisplatin in patients with completely resected stage I or II carcinosarcomas (mixed mesodermal tumors) of the uterus: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Phase II trial of ifosfamide and mesna in mixed mesodermal tumors of the uterus (a Gynecologic Oncology Group study).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Phase II evaluation of topotecan in carcinosarcoma of the uterus: a Gynecologic Oncology Group study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

A phase II study of sorafenib in advanced uterine carcinoma/carcinosarcoma: a trial of the Chicago, PMH, and California Phase II Consortia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Efficacy and safety of imatinib mesylate (Gleevec) and immunohistochemical expression of c-Kit and PDGFR-beta in a Gynecologic Oncology Group Phase Il Trial in women with recurrent or persistent carcinosarcomas of the uterus

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Immunohistochemical evaluation of KIT expression in sarcomas of the gynecologic region

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

c-Kit expression in patients with uterine leiomyosarcomas: a potential alternative therapeutic treatment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Identification of genotype-correlated sensitivity to selective kinase inhibitors by using high-throughput tumor cell line profiling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Cancer. Addiction to oncogenes--the Achilles heal of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

Patterns of somatic mutation in human cancer genomes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

"Oncogenic shock": explaining oncogene addiction through differential signal attenuation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2010.11.039

10.1016/J.YGYNO.2010.11.039

7 January 2021

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:21168197%20AND%20SRC:MED&resulttype=core&format=json

18 January 2020

1 reference